Dr. Warren Heymann, Director of the American Board of Dermatology, reflects on a career shaping the field of dermatology. Initially drawn to internal medicine, a dermatology elective revealed a passion for the specialty, a stark contrast to the less competitive landscape of 1979.
The field has rapidly advanced, particularly with the advent of targeted biologic therapies for conditions like psoriasis and atopic dermatitis. However, Heymann notes a significant gap: a lack of comparative studies to determine the optimal biologic for each individual. Current prescription decisions are often influenced by insurance coverage rather than purely clinical efficacy.
Teledermatology emerged as a critical tool during the COVID-19 pandemic, offering accessible care, though Heymann acknowledges its limitations compared to in-person consultations, particularly for physical examinations and procedures like biopsies. Unintended consequences of new therapies, such as paradoxical psoriasis with biologics or the debate around unmasking cutaneous T cell lymphoma with certain treatments, highlight the ongoing learning curve in managing these powerful medications.
Artificial Intelligence (AI) is revolutionizing research and clinical practice by enabling rapid literature review and information retrieval. Heymann stresses the importance of fundamental medical knowledge to critically evaluate AI-generated insights and avoid misinformation. Safeguards for responsible AI use, he emphasizes, include a healthy skepticism and verification of AI-sourced information against original research.
An exceptional dermatologist, according to Heymann, is distinguished not only by knowledge but by heart, compassion, and unwavering curiosity. Attention to detail is crucial, enabling the recognition of subtle signs that may indicate underlying systemic issues. While specialization has increased dramatically with growing knowledge, the core of great practice remains a deep commitment to patient well-being.
Over decades, dermatologic surgery, pediatric dermatology, and the understanding of genetic skin disorders have undergone profound transformations. Advances in imaging and targeted therapies have dramatically improved outcomes for previously intractable conditions, such as metastatic melanoma, now often curable. Biologics have revolutionized psoriasis treatment, offering near-complete clearance where once partial improvement was considered a success.
Reflecting on his career, Dr. Heymann is most proud of establishing an academic division of dermatology at Cooper Medical School of Rowan University. This initiative fostered teaching and research, enabling him to contribute to medical education and publications. His advice to future physicians is to set high goals, pursue continuous learning, and never become complacent.